A Tyrosine Adsorbed Modified Grass Allergen + MPL SCIT Demonstrates Clinically Improvement in Combined Symptom and Medication Score in Subjects with Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis

L.m Dubuske ,Chris Smith,Ellen Sher,Margret Jandl,William Greisner,Margitta Worm,Marion Seybold,Jonathan Matz,Sabine Laßmann,Markus Berger,Kemi Oluwayi,Matthias Kramer,David Cypcar,Mandy Cuevas,Stefan Zielen,Uwe Berger,Gary Steven,Annette Fuhr-Horst,Murray A Skinner ,Jonathan A Bernstein ,P.j De Kam

doi:10.1016/j.jaci.2021.12.016

Abstract

An exploratory field study with a modified grass allergen subcutaneous immunotherapy (SCIT) product using MicroCrystalline Tyrosine (MCT) and Monophosphoryl Lipid A (MPL) as an adjuvant system was conducted to optimize a planned pivotal Phase III study.

Full Text